Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 29, 2016
Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial
Go Kimura, Junji Yonese, Takashi Fukagai, et al.
Alimentary Pharmacology & Therapeutics
|
September 18, 2023
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis
Naim Alkhouri, Donald Lazas, Rohit Loomba, et al.
Neurology
|
May 1, 2019
A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
Hanns Lochmüller, Anthony Behin, Yoseph Caraco, et al.
The Lancet. Gastroenterology & Hepatology
|
December 15, 2022
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
Rohit Loomba, Eric J Lawitz, Juan Pablo Frias, et al.
Nature Medicine
|
June 24, 2023
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Deepak L Bhatt, Harold E Bays, Michael Miller, et al.
Nature Medicine
|
March 4, 2024
Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Deepak L Bhatt, Harold E Bays, Michael Miller, et al.
Clinical Genitourinary Cancer
|
March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial
Joshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
The New England Journal of Medicine
|
June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Rohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
European Urology
|
March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Christopher P Evans, Celestia S Higano, Thomas Keane, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 29, 2016
Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial
Go Kimura, Junji Yonese, Takashi Fukagai, et al.
Alimentary Pharmacology & Therapeutics
|
September 18, 2023
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis
Naim Alkhouri, Donald Lazas, Rohit Loomba, et al.
Neurology
|
May 1, 2019
A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
Hanns Lochmüller, Anthony Behin, Yoseph Caraco, et al.
The Lancet. Gastroenterology & Hepatology
|
December 15, 2022
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
Rohit Loomba, Eric J Lawitz, Juan Pablo Frias, et al.
Nature Medicine
|
June 24, 2023
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Deepak L Bhatt, Harold E Bays, Michael Miller, et al.
Nature Medicine
|
March 4, 2024
Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Deepak L Bhatt, Harold E Bays, Michael Miller, et al.
Clinical Genitourinary Cancer
|
March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial
Joshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
The New England Journal of Medicine
|
June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Rohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
European Urology
|
March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Christopher P Evans, Celestia S Higano, Thomas Keane, et al.
Page
of 2